CN114712475B - Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof - Google Patents
Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof Download PDFInfo
- Publication number
- CN114712475B CN114712475B CN202210505279.3A CN202210505279A CN114712475B CN 114712475 B CN114712475 B CN 114712475B CN 202210505279 A CN202210505279 A CN 202210505279A CN 114712475 B CN114712475 B CN 114712475B
- Authority
- CN
- China
- Prior art keywords
- extract
- turmeric
- rattan
- sappan wood
- sappan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia, which is prepared from the following raw materials in parts by weight: 4-1 parts of turmeric, 2-1 parts of sappan wood and 2-1 parts of heart-shaped rattan. The composition can relieve H9C2 myocardial cell injury caused by hypoxia/reoxygenation, has the activity of resisting myocardial ischemia reperfusion injury, and particularly has the best activity when turmeric, sappan wood and rattan extract are mixed according to the ratio of 2:1:1. Compared with the traditional Chinese medicine compound which is reported at present, the traditional Chinese medicine compound can relieve the pain of the clinical MIRI patient by using fewer medicinal herbs, and has the value of clinical popularization and application.
Description
Technical Field
The invention particularly relates to a Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia.
Background
Reperfusion Injury (MIRI) refers to the pathological process of progressive exacerbation of tissue injury, although the ischemic myocardium is restored to normal perfusion, after partial or complete acute occlusion of the coronary arteries, and when recanalization is regained for a certain period of time. The myocardial ultrastructural, energy metabolism, cardiac function and electrophysiology changes caused by ischemia are more prominent after vascular recanalization, and even serious arrhythmia can occur to cause sudden death.
Prevention and treatment of myocardial ischemia reperfusion injury includes: scavenging free radicals, treating with "post-ischemia adaptation", inhibiting Na+F/H+, na+/Ca2+ ion exchange, and using adenosine receptor agonist, magnesium agent, statin, angiotensin receptor antagonist, etc. However, the application of these drugs has not been widely developed clinically so far, and the efficacy is uncertain, and further research and verification are required.
The traditional Chinese medicine has definite MIRI treatment effect, the experimental research has made considerable progress, and the prospect in the aspect of MIRI treatment is wide. Li Ji, etc., the research progress of the traditional Chinese medicine for treating myocardial ischemia reperfusion injury [ J ], the report of traditional Chinese medicine, 2015, 43 (2) discloses that traditional Chinese medicine compound honey-fried licorice root soup, cassia twig licorice root soup, flavored pulse-activating decoction and the like have the effect of resisting myocardial ischemia reperfusion injury, but the traditional Chinese medicine has a plurality of medicines, has high cost, and needs to develop safer, more effective and economic traditional Chinese medicine formulas for relieving the pain of clinical MIRI patients.
Disclosure of Invention
In order to solve the problems, the invention provides a Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia, which is prepared from the following raw materials in parts by weight:
10-30 parts of turmeric, 20-30 parts of sappan wood and 20-30 parts of heart-shaped rattan.
Further, the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
18-24 parts of turmeric, 25-30 parts of sappan wood and 25-30 parts of heart-shaped rattan.
Further, the preparation is an oral preparation prepared by taking medicinal powder of the raw material medicine or water or organic solvent extract of the raw material medicine as an active ingredient and adding pharmaceutically acceptable auxiliary materials; the oral preparation is granule, paste, powder, pill or solution.
Furthermore, the oral preparation is prepared by taking the aqueous extract of turmeric, the alcohol extract of sappan wood and the alcohol extract of the climbing fern as active ingredients and adding pharmaceutically acceptable auxiliary materials.
Further, the mass ratio of the aqueous extract of turmeric to the alcohol extract of sappan wood to the alcohol extract of the centering rattan in the oral preparation is 1-4: 1-2: 1-2, preferably 2:1:1.
further, the water extract of turmeric is obtained by extracting turmeric with water, loading the extract on a macroporous resin column, eluting with 75% methanol, loading the extract on the macroporous resin column, eluting with 60% methanol;
the alcohol extract of sappan wood is an extract of sappan wood extracted by 80% ethanol;
the alcohol extract of the rattan is an extract of the rattan extracted by 80% alcohol.
The invention also provides a preparation method of the Dai medicine composition, which comprises the following steps:
(1) Weighing the raw materials according to the proportion;
(2) Extracting Curcuma rhizome with water, loading the extractive solution onto macroporous resin column, eluting with 75% methanol, concentrating the eluate, loading onto macroporous resin column, eluting with 60% methanol, collecting eluate, concentrating, and drying to obtain Curcuma rhizome extract; extracting lignum sappan with 80% ethanol, concentrating the extractive solution, and drying to obtain lignum sappan extract; extracting caulis Sargentodoxae with 80% ethanol, concentrating the extractive solution, and drying to obtain lignum sappan extract;
(3) And (3) adding auxiliary materials or auxiliary components commonly used in medicines into the turmeric extract, the sappan wood extract and the rattan extract obtained in the step (2).
The invention finally provides application of the Dai medicine composition in preparing medicines for preventing and/or treating reperfusion injury after myocardial ischemia.
Further, the drug is a drug for inhibiting the ST-segment shift of an electrocardiogram caused by reperfusion after myocardial ischemia.
Further, the drug is a drug for reducing myocardial infarction area caused by reperfusion after myocardial ischemia.
Dai medicine 'four-tower theory' considers that symptoms such as palpitation, chest distress, shortness of breath and the like are related to ischemic heart diseases and MIRI, at the moment, four-tower dysfunction in the body, deficiency of wind and fire towers (qi and blood), fire failure to produce water, accumulation of heart and chest, chest distress and distending pain caused by unsmooth qi and blood stasis, heart and chest failure in warm-keeping, abnormal heart, palpitation caused by weak water and blood transportation, and chest distress, shortness of breath caused by biochemical failure of water and blood due to weak soil tower. In the medicine composition, turmeric (rhizome of Curcuma longa of Curcuma genus of Zingiberaceae) is used as a main medicine, has smelly taste, is bitter and slightly spicy, has flat property and is hot, enters soil, water and wind tower, and has the effects of clearing away heat and toxic materials, activating blood circulation to stop pain, promoting qi circulation and removing blood stasis; sappan wood (heart wood of Caesalpinia sappan wood Caesalpinia sappan of Leguminosae) has slightly sweet taste, mild nature, and is added into water and Fengtao for promoting blood circulation, removing blood stasis, and relieving swelling and pain; the taste of the centering rattan (rattan of centering rattan Mappianthus iodoides of genus centering rattan of family Theaceae) is sweet, cool, enter soil, fire and wind tower, clear fire and center, promote bile flow and alleviate jaundice, ventilate and alleviate pain. Sappan wood and the centering rattan are auxiliary drugs, and auxiliary main drugs enhance the curative effect. The three medicines are combined to have the effects of tonifying wind, fire and soil tower, and achieve the purposes of warming and activating qi, tonifying fire, enriching blood and calming heart.
Cell tests prove that the composition can relieve H9C2 myocardial cell injury caused by hypoxia/reoxygenation, has the activity of resisting myocardial ischemia reperfusion injury, and particularly has the best activity of resisting myocardial ischemia reperfusion injury when turmeric, sappan wood and rattan extracts are mixed according to the ratio of 2:1:1. Compared with the traditional Chinese medicine compound which is reported at present, the traditional Chinese medicine compound can relieve the pain of the clinical MIRI patient by using fewer medicinal herbs, and has the value of clinical popularization and application.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Drawings
Fig. 1: H9C2 cell H/R model
Fig. 2: effect of Dai medicine composition pretreatment with high, medium and low dosages on H/R treatment H9C2 myocardial cell viability
Fig. 3: effect of Dai medicine composition pretreatment with high, medium and low dosages on LDH release of H9C2 myocardial cells in H/R treatment
Fig. 4: effects of Dai medicine composition pretreatment of turmeric, sappan wood and Boehmeria nivea extracts mixed according to different proportions on H/R treatment H9C2 myocardial cell viability
Fig. 5: effects of Dai medicine composition pretreatment of turmeric, sappan wood and Boehmeria nivea extracts mixed according to different proportions on H/R treatment H9C2 myocardial cell viability
Detailed Description
EXAMPLE 1 preparation of the medicament of the invention
The formula comprises the following components: 20g of turmeric, 30g of sappan wood and 25g of heart-shaped rattan.
The preparation method comprises the following steps:
1) Preparation of turmeric extract: pulverizing Curcuma rhizome root, extracting with 5-8 times of hot water (100deg.C), concentrating the extractive solution to obtain extract, loading onto macroporous resin column (LX-T28 macroporous resin, siAN blue and technology New Material Co., ltd.), eluting with 8-10 column volume of 75% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, loading onto macroporous resin column, eluting with 5-6 column volume of 60% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, and lyophilizing to obtain Curcuma rhizome extract 2g;
2) Preparation of sappan wood extract: taking dried sappan wood, pulverizing, adding 80% edible ethanol with weight of 8 times, and soaking for 48 hr. Ultrasonic extracting at 50deg.C under 15KHz power for 90min, filtering to obtain filtrate, repeating ultrasonic extraction for 3 times, mixing filtrates, and concentrating under reduced pressure at 50deg.C to obtain solution with density of 1.15-1.20. Lyophilizing the concentrated solution to obtain lignum sappan extract 1g;
3) Preparation of the extract of Boschniakia rossica: taking dried rattan stems, crushing, adding 80% edible ethanol with the weight of 8 times of the rattan stems, and soaking for 48 hours. Extracting with 15KHz ultrasonic wave at 50deg.C for 90min, filtering to obtain filtrate, repeating ultrasonic extraction for 3 times, mixing filtrates, concentrating under reduced pressure at 50deg.C to obtain concentrated solution with density of 1.15-1.20, and lyophilizing to obtain 1g of herba Solani Lyrati extract;
4) And (3) adding auxiliary materials or auxiliary components commonly used in medicines into the turmeric extract obtained in the step (1), the sappan wood extract obtained in the step (2) and the centering rattan extract obtained in the step (3).
EXAMPLE 2 preparation of the medicament of the invention
The formula comprises the following components: 18g of turmeric, 25g of sappan wood and 25g of heart-shaped rattan.
The preparation method comprises the following steps: the preparation method comprises the following steps: 1) Preparation of turmeric extract: pulverizing Curcuma rhizome root, extracting with 5-8 times of hot water (100deg.C), concentrating the extractive solution to obtain extract, loading onto macroporous resin column (LX-T28 macroporous resin, siAN blue and technology New Material Co., ltd.), eluting with 8-10 column volume of 75% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, loading onto macroporous resin column, eluting with 5-6 column volume of 60% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, and lyophilizing to obtain Curcuma rhizome extract;
2) Preparation of sappan wood extract: taking dried sappan wood, pulverizing, adding 80% edible ethanol with weight of 8 times, and soaking for 48 hr. Ultrasonic extracting at 50deg.C under 15KHz power for 90min, filtering to obtain filtrate, repeating ultrasonic extraction for 3 times, mixing filtrates, and concentrating under reduced pressure at 50deg.C to obtain solution with density of 1.15-1.20. Lyophilizing the concentrated solution to obtain lignum sappan extract;
3) Preparation of the extract of Boschniakia rossica: taking dried rattan stems, crushing, adding 80% edible ethanol with the weight of 8 times of the rattan stems, and soaking for 48 hours. Extracting with 15KHz ultrasonic wave at 50deg.C for 90min, filtering to obtain filtrate, repeating ultrasonic extraction for 3 times, mixing filtrates, concentrating under reduced pressure at 50deg.C to obtain concentrated solution with density of 1.15-1.20, and lyophilizing to obtain herba Solani Lyrati extract;
4) And (3) adding auxiliary materials or auxiliary components commonly used in medicines into the turmeric extract obtained in the step (1), the sappan wood extract obtained in the step (2) and the centering rattan extract obtained in the step (3).
EXAMPLE 3 preparation of the medicament of the invention
The formula comprises the following components: 24g of turmeric, 30g of sappan wood and 30g of heart-shaped rattan.
The preparation method comprises the following steps: the preparation method comprises the following steps: 1) Preparation of turmeric extract: pulverizing Curcuma rhizome root, extracting with 5-8 times of hot water (100deg.C), concentrating the extractive solution to obtain extract, loading onto macroporous resin column (LX-T28 macroporous resin, siAN blue and technology New Material Co., ltd.), eluting with 8-10 column volume of 75% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, loading onto macroporous resin column, eluting with 5-6 column volume of 60% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, and lyophilizing to obtain Curcuma rhizome extract;
2) Preparation of sappan wood extract: taking dried sappan wood, pulverizing, adding 80% edible ethanol with weight of 8 times, and soaking for 48 hr. Ultrasonic extracting at 50deg.C under 15KHz power for 90min, filtering to obtain filtrate, repeating ultrasonic extraction for 3 times, mixing filtrates, and concentrating under reduced pressure at 50deg.C to obtain solution with density of 1.15-1.20. Lyophilizing the concentrated solution to obtain lignum sappan extract;
3) Preparation of the extract of Boschniakia rossica: taking dried rattan stems, crushing, adding 80% edible ethanol with the weight of 8 times of the rattan stems, and soaking for 48 hours. Extracting with 15KHz ultrasonic wave at 50deg.C for 90min, filtering to obtain filtrate, repeating ultrasonic extraction for 3 times, mixing filtrates, concentrating under reduced pressure at 50deg.C to obtain concentrated solution with density of 1.15-1.20, and lyophilizing to obtain herba Solani Lyrati extract;
4) And (3) adding auxiliary materials or auxiliary components commonly used in medicines into the turmeric extract obtained in the step (1), the sappan wood extract obtained in the step (2) and the centering rattan extract obtained in the step (3).
The advantageous effects of the present invention are described below by way of test examples.
Test example 1
1. The anti-myocardial ischemia reperfusion injury activity of turmeric, sappan wood and rattan extracts was studied using an H9C2 cardiomyocyte hypoxia/reoxygenation (H/R) model.
(1) Test materials
H9C2 cells: purchased from Guangzhou Saikovia Biotechnology Co., ltd
Reagents and kits: fetal bovine serum (Vivacell, 2147381); culture medium (Guangzhou Saikovia Biotechnology Co., ltd., 13725001); PBSPBS (guangzhou racing biotech limited, 08920001); low sugar medium (BI, 0022219); sugarless medium (BI, 1914465); DMSO (melengo, J0805A); cell viability assay (CCK-8) kit (Proteintech, 19010311); lactate Dehydrogenase (LDH) kit (solebao, 50T, 19220117).
Positive control: compound red sage root granule, 1 g/bag, zhuhai Jin Hong pharmaceutical industry Co., ltd., lot number: 194017.
Instrument apparatus: three gas incubator (i 160, U.S. Thermo Scientific Forma), inverted microscope (DMi 1, leika microscopy System (Shanghai) trade Co., ltd.), microplate reader (Varioskan Flash, U.S. Thermofiser)
(2) Experimental method
Preparing an object to be measured: turmeric, sappan wood, celastrus orbiculatus extract, positive control prepared as in example 1 were diluted to high dose 240 μg/mL, medium dose 120 μg/mL, low dose 60 μg/mL with complete medium containing 1% dmso, respectively; dai medicine composition high dose group: diluting with complete culture medium containing 1% DMSO, wherein each milliliter contains 80 μg of Curcuma rhizome, lignum sappan, and caulis Seu folium Ampelopsis Brevipedunculatae extract; dose group in Dai medicine composition: diluting with complete culture medium containing 1% DMSO, and 40 μg each of Curcuma rhizome, lignum sappan, and caulis Seu folium Ampelopsis Brevipedunculatae extract per ml; dai medicine composition low dose group: diluted with complete medium containing 1% dmso, 20 μg each per ml of turmeric, sappan wood, and centering vine extract.
H/R treatment: H9C2 cells were added with complete medium (high sugar DMEM-H medium containing 10% fetal bovine serum, penicillin 100U/ml, streptomycin 100U/ml and 5-bromodeoxyuridine 10. Mu. Mol/L), 37℃and 5% CO 2 Culturing for 48-60 hr with relative humidity of 70-80%, collecting logarithmic growth phase cells, and mixing with the culture medium according to 1×10 6 A density of cell/100. Mu.L was seeded into 96-well plates at 200. Mu.L per well and H/R treatment was performed as described in FIG. 1.
Grouping: A. normal group, 3 rd step with complete medium containing 1% DMSO, 1 st-2, 4-5 th steps with complete medium, 37℃and 5% CO 2 Relative humidity 70-80%; B.H/R group, step 3, complete medium with 1% DMSO was added, the remainder being as in FIG. 1; C. and (3) treating the group, wherein the to-be-detected substances are respectively added in the step 3, and the rest operations are the same as the H/R group and the D positive control group. Step 3, positive controls with high, medium and low doses are added respectively, and the rest operation is the same as that of the H/R group. Each group of 6-9 duplicate wells was repeated 3 times.
Cell viability was measured by CCK-8 method: mu.L of CCK-8 solution was added to each well, incubated in a three-gas incubator for 1h, and absorbance was measured at 450nm using an enzyme-labeled instrument. Cell viability = [ (a) Compound treatment group -A H/R group ) /(A Normal group -A H/R group )]×100％。
The kit is used for measuring the activity of a myocardial cell injury marker Lactate Dehydrogenase (LDH): 100 μl of cell supernatant was aspirated from each well and transferred to a corresponding well of a new 96-well plate, and LDH activity was determined by the kit instructions. LDH Activity= [ (LDH) H/R group -LDH Compound treatment group )/(LDH H/R group -LDH Normal group )]×100％。
The statistical method comprises the following steps: statistical analysis was performed using SPSS 17.0 software. Mean ± standard deviation of results
The comparison of multiple groups of data adopts single-factor analysis of variance, and the two groups of data are statistically significant by using P < 0.05 as a difference.
(3) Experimental results
The high, medium and low doses of turmeric, sappan wood and rattan extract can relieve H9C2 myocardial cell injury caused by hypoxia/reoxygenation to a certain extent.
Compared with the extracts of turmeric, sappan wood and rattan with single concentration, the Dai medicine composition composed of turmeric, sappan wood and rattan extract has obvious enhancement in improving the activity of myocardial cells and inhibiting the release of LDH (figure 2).
The activity of H9C2 cells is superior to that of positive control (figure 2) at medium dosage, namely 40 mug of turmeric, sappan wood and rattan extract per milliliter; the Dai medicine composition has LDH release rate smaller than that of positive control (figure 3) at high, medium and low dosages.
The results indicate that the Dai medicine composition pretreatment consisting of turmeric, sappan wood and rattan extract can relieve H9C2 myocardial cell injury caused by hypoxia/reoxygenation to a certain extent, has activity of resisting myocardial ischemia reperfusion injury, and has dose dependency. Compared with the activity of the positive control medicine under the same dosage, the difference between the Dai medicine composition with the medium dosage and the positive control medicine is the largest, so that the activity of resisting myocardial ischemia reperfusion injury of 120 mug/mL of the medium dosage is determined to be the best, namely, the activity of resisting myocardial ischemia reperfusion injury when 40 mug of turmeric, sappan wood and rattan extract is contained in each milliliter.
2. And (3) screening the optimal matching proportion of turmeric, sappan wood and rattan extracts by using an H9C2 myocardial cell hypoxia/reoxygenation (H/R) model.
(1) Experimental materials and experimental methods were the same as (one) (1).
(2) Experimental methods.
Preparing an object to be measured: the positive control was diluted to 120. Mu.g/mL with complete medium containing 1% DMSO. Turmeric, sappan wood, and rattan extracts prepared as in example 1 were formulated in the following different ratios (1:4:1:1 groups per milliliter with turmeric extract 80 μg, sappan wood extract 20 μg, rattan extract 20 μg) with complete medium with 1% dmso; (2) group 2:1:1, containing 60 μg turmeric extract, 30 μg sappan wood extract, 30 μg centering vine extract per milliliter; (3) 1:1:1 group containing 40 μg of turmeric extract, 40 μg of sappan wood extract, 40 μg of crotalaria extract per milliliter; (4) group 1:2:2. Each milliliter contains 24 mug of turmeric extract, 48 mug of sappan wood extract and 48 mug of rattan extract.
The rest of the experimental methods are the same as those of the first embodiment
(3) Experimental results
Turmeric, sappan wood and rattan extract are mixed according to the ratio of 4:1:1,2:1:1,1:1:1 and 1:2:2, so that the activity of myocardial cells can be improved to a certain extent (figure 4), the release of myocardial cells LDH caused by H/R injury is inhibited (figure 4), the activity of the composition is slightly better than that of a positive control, and Dai medicine composition formed by mixing turmeric, sappan wood and rattan extract according to the ratio of 2:1:1 has the best effect on relieving H9C2 myocardial cells injury caused by hypoxia/reoxygenation (figure 5). The results indicate that Dai medicine composition formed by mixing turmeric, sappan wood and rattan extract according to the proportion of 2:1:1 has the best activity of resisting myocardial ischemia reperfusion injury.
In conclusion, the composition can relieve H9C2 myocardial cell injury caused by hypoxia/reoxygenation, has the activity of resisting myocardial ischemia reperfusion injury, and particularly has the best activity when turmeric, sappan wood and rattan extracts are mixed according to the ratio of 2:1:1. Compared with the traditional Chinese medicine compound which is reported at present, the traditional Chinese medicine compound can relieve the pain of the clinical MIRI patient by using fewer medicinal herbs, and has the value of clinical popularization and application.
Claims (4)
1. Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia, which is characterized in that: the oral preparation is prepared by taking an aqueous extract of turmeric, an alcohol extract of sappan wood and an alcohol extract of climbing fern as active ingredients and adding pharmaceutically acceptable auxiliary materials;
the mass ratio of the aqueous extract of turmeric to the alcohol extract of sappan wood to the alcohol extract of the centering rattan in the oral preparation is 1-4: 1-2: 1-2;
the water extract of turmeric is prepared by extracting turmeric with water, loading the extractive solution on a macroporous resin column, eluting with 75% methanol, loading the eluate on the macroporous resin column, and eluting with 60% methanol;
the alcohol extract of sappan wood is an extract of sappan wood extracted by 80% ethanol;
the alcohol extract of the rattan is an extract of the rattan extracted by 80% alcohol.
2. The Dai medicine composition according to claim 1, wherein: the mass ratio of the water extract of turmeric, the alcohol extract of sappan wood and the alcohol extract of the centering rattan in the oral preparation is 2:1:1.
3. the method for preparing the Dai medicine composition according to claim 1 or 2, which is characterized in that: it comprises the following steps:
(1) Weighing turmeric, sappan wood and caulis Aristolochiae Kaempferi as raw materials;
(2) Extracting Curcuma rhizome with water, loading the extractive solution onto macroporous resin column, eluting with 75% methanol, concentrating the eluate, loading onto macroporous resin column, eluting with 60% methanol, collecting eluate, concentrating, and drying to obtain Curcuma rhizome extract; extracting lignum sappan with 80% ethanol, concentrating the extractive solution, and drying to obtain lignum sappan extract; extracting caulis Sargentodoxae with 80% ethanol, concentrating and drying the extractive solution to obtain extract;
(3) Mixing the turmeric extract, the sappan wood extract and the rattan extract obtained in the step 2) according to the mass ratio, and adding pharmaceutically acceptable auxiliary materials.
4. Use of the Dai medicine composition according to claim 1 or 2 for the preparation of a medicament for the prevention and/or treatment of reperfusion injury after myocardial ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210505279.3A CN114712475B (en) | 2022-05-10 | 2022-05-10 | Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210505279.3A CN114712475B (en) | 2022-05-10 | 2022-05-10 | Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114712475A CN114712475A (en) | 2022-07-08 |
| CN114712475B true CN114712475B (en) | 2023-06-16 |
Family
ID=82232156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210505279.3A Active CN114712475B (en) | 2022-05-10 | 2022-05-10 | Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114712475B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413655A (en) * | 2002-10-14 | 2003-04-30 | 刘建勋 | Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method |
| CN107693597A (en) * | 2017-08-18 | 2018-02-16 | 裴非 | A kind of Chinese medicine composition to resist myocardial ischemia and its preparation method and application |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101317997B (en) * | 2007-06-08 | 2011-01-19 | 中国科学院大连化学物理研究所 | Preparation for effective component of turmeric |
| CN113456621B (en) * | 2021-08-26 | 2022-06-21 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Application of curcumin metabolite in preparation of medicine for treating myocardial ischemia-related injury |
-
2022
- 2022-05-10 CN CN202210505279.3A patent/CN114712475B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413655A (en) * | 2002-10-14 | 2003-04-30 | 刘建勋 | Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method |
| CN107693597A (en) * | 2017-08-18 | 2018-02-16 | 裴非 | A kind of Chinese medicine composition to resist myocardial ischemia and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 傣族治疗产后病的药用民族植物学研究;刘颖颖;姚昕;李海涛;李晓花;马小军;;中草药;47(23);第4301-4304页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114712475A (en) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112274620B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia, preparation method, detection method and application thereof | |
| US6447814B1 (en) | Chinese herbal composition for improving blood circulation and the method of preparing the same | |
| CN1985864B (en) | Medicine composition prepared mainly from glycyrrhizic acid or its salt, ginseng and glossy ganoderma | |
| US9303006B2 (en) | Line leaf inula flower lactone A and methods for preparing and using the same for treating myocarditis | |
| JP2002538214A (en) | Pharmaceutical composition for treating cardiovascular disease and method for producing the same | |
| WO2008064592A1 (en) | A composition comprising chinese traditional medicine as active ingredient for treating cardiovascular diseases and quality control method thereof | |
| CN114712475B (en) | Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN1899415B (en) | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method | |
| KR20100019370A (en) | Anti-anal composition and process for its manufacture | |
| CN1923228B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and ligustrazine | |
| CN1985873A (en) | Medicine composition of glycyrrhizic acid or its salt, ginseng and astragalus root | |
| CN102813713A (en) | Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition | |
| CN109331107B (en) | Traditional Chinese medicine composition and oral liquid for preventing and treating pet viral myocarditis and preparation method thereof | |
| KR100376030B1 (en) | crude drug for 2type diabetes | |
| CN112089738A (en) | Preparation method and application of caulis sinomenii extract | |
| CN1215876C (en) | Antigout medicinal composition and its preparing method | |
| CN108743654B (en) | Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof | |
| CN109758570A (en) | A kind of pair of alcoholic liver injury has the composition and its health care product, application of auxiliary protection function | |
| CN116059292B (en) | Traditional Chinese medicine composition for treating heart failure and preparation process thereof | |
| CN114736182B (en) | Compound for resisting myocardial ischemia reperfusion injury, dai medicine composition and application thereof | |
| US20240156891A1 (en) | Extracts of salvia miltiorrhiza and/or poncirus trifoliata for inhibiting body weight gain | |
| CN111773258B (en) | Mongolian medicine for resisting influenza virus, pharmaceutical composition, preparation method and application thereof | |
| CN104547027B (en) | Preparation method and application of salvia miltiorrhiza leave and panax notoginseng leaf extract | |
| CN102727850B (en) | Medicinal composition for treating AIDS, a preparation method thereof, a quality control method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |